In vitro inhibitory effect of miltefosine against strains of Histoplasma capsulatum var. capsulatum and Sporothrix spp.

Medical Mycology

Volumn 52, Issue 3, 2014, Pages 320-325

  Brilhante, Raimunda Sâmia Nogueira ^a   Malaquias, Ângela Donato Maia ^a   Caetano, Érica Pacheco ^a   De Souza Collares Maia Castelo Branco, Débora ^a   De Lima, Rita Amanda Chaves ^a   De Farias Marques, Francisca Jakelyne ^a   Silva, Natalya Fechine ^a   De Alencar, Lucas Pereira ^a,b   Monteiro, André Jalles ^a   De Camargo, Zoilo Pires ^c   De Jesus Pinheiro Gomes Bandeira, Tereza ^a,d   Rodrigues, Anderson Messias ^c   De Aguiar Cordeiro, Rossana ^a   Moreira, José Luciano Bezerra ^a   Sidrim, José Júlio Costa ^a   Rocha, Marcos Fábio Gadelha ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Christus College   (Brazil)

Author keywords

Histoplasma capsulatum; inhibitory effect; miltefosine; Sporothrix spp.

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MILTEFOSINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HISTOPLASMA CAPSULATUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPOROTHRIX; SPOROTHRIX BRASILIENSIS; SPOROTHRIX GLOBOSA; SPOROTHRIX MEXICANA; SPOROTHRIX SCHENCKII;

HISTOPLASMA CAPSULATUM; INHIBITORY EFFECT; MILTEFOSINE; SPOROTHRIX SPP.;

ANTIFUNGAL AGENTS; HISTOPLASMA; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PHOSPHORYLCHOLINE; SPOROTHRIX;

EID: 84898910035     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myt027     Document Type: Article

References (34)

1. Silveira CP, Torres-Rodr?guez JM, Alvarado-Ram?rez E et al. MICs and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazole and terbinafine in Sporothrix schenckii. J Med Microbiol 2009; 58: 1607-1610.
2. Madrid IM, Mattei AS, Fernandes CG et al. Epidemiological findings and laboratory evaluation of sporotrichosis: A description of 103 cases in cats and dogs in Southern Brazil. Mycopathologia 2011; 173: 265-273.
3. Kauffman CA. Histoplasmosis. Clin Chest Med 2009; 30: 217-225.
4. Brilhante RSN, FechineMAB,Mesquita JRL et al. Histoplasmosis in HIV-positive patients in Cear? a, Brazil: Clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates. Trans Royal Soc Trop Med Hyg 2012; 106: 484-488.
5. Barros MBL, Paes RA, Schubach AO. Sporothrix schenckii and sporotrichosis. Clin Microbiol Rev 2011; 24: 633-654.
6. Rodrigues AM, De Hoog S, De Camargo ZP. Emergence of pathogenicity in the Sporothrix schenckii complex. Med Mycol 2013; 51: 405-412.
7. Marimon R, Serena C, Gen?e J et al. In vitro antifungal susceptibilities of five species of Sporothrix. Antimicrob Agent Chemother 2008; 52: 732-734.
8. Wheat LJ, Freifeld AG, KleimanMBet al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 807-825.
9. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45: 1255-1265.
10. Schubach TMP, Schubach AO, Okamoto T et al. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). J Am Vet Med Assoc 2004; 224: 1623-1629.
11. Wheat LJ, Connolly P, Smedema M et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antim Chem 2006; 57: 1235-1239.
12. Brilhante RSN, Fechine MAB, Cordeiro RA et al. In vitro effect of sulfamethoxazole-trimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother 2010; 54: 3978-3979.
13. Cordeiro RA, Marques FJF, Brilhante RSN et al. Synergistic effect of antituberculosis drugs and azoles in vitro against Histoplasma capsulatum var. capsulatum. Antimicrob Agent Chemother 2011; 55: 4482-4484.
14. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 11: 508-512.
15. Soto J, Soto P. Miltefosine: Oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006; 4: 177-185.
16. Luna KP, Hern?andez IP, Rueda CM et al. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biom?edica 2009; 29: 448-455.
17. Widmer F, Wright LC, Obando D et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50: 414-421.
18. Tong Z, Widmer F, Sorrell TC et al. In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes. Antimicrob Agent Chemother 2007; 51: 2219-2222.
19. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungicidal Susceptibility Testing of Yeasts, 3nd ed. CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
20. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, 2nd ed. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
21. Alvarado-Ram?rez E, Torres-Rodr?guez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods. Antimicrob Agents Chemother 2007; 51: 2420-2423.
22. Cantón E, Pem?an J, Viudes A et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 2003; 45: 203-206.
23. Moreira RA, Mendanha SA, Hansen D, Alonso A. Interaction of miltefosine with the lipid and protein components of the erythrocyte membrane. J Pharm Sci 2013; 102: 1661-1669
24. Dorlo TPC, Balasegaram M, Beijnen JH, De Vries PJ. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67: 2576-2597.
25. Keenan PO, Knight AW, Billinton N et al. Clear and present danger The use of a yeast biosensor to monitor changes in the toxicity of industrial effluents subjected to oxidative colour removal treatments. J Environ Monitor 2007; 9: 1394-1401.
26. Zuo X, Djordjevic JT, Oei JB et al. Miltefosine induces apoptosis-like cell death in yeast via cox9p in cytochrome c oxidase. Mol Pharmacol 2011; 80: 476-485.
27. Shubitz LF, Nix DE,MartinezMet al.Miltefosine (MF) in vitro and in vivo against Coccidioides. In: Catanzaro A, Blair JE, Ampel N, ed. Proceedings of the 55th Annual Coccidioidomycosis Study Group,Davis, CA, USA, apr. 2 2011. Arizona, USA:Mayo Clinic Arizona, 2011
28. Wiederhold NP, Najvar LK, Bocanegra R et al. Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Antimicrob Agent Chemother 2013; 57: 745-750.
29. Dorlo TPC, Van Thiel PPAM, Huitema ADR et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agent Chemother 2008; 52: 2855-2860.
30. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-1746.
31. Wheat LJ. Current diagnosis of histoplasmosis. Trends Microbiol 2003; 11: 488-494.
32. Cordeiro RA, Coelho CGV, Brilhante RSN et al. Serological evidence of Histoplasma capsulatum infection among dogs with leishmaniasis in Brazil. Acta Tropica 2011; 119: 203-205.
33. Miranda LHM, Quintella LP, Menezes RC et al. Evaluation of immunohistochemistry for the diagnosis of sporotrichosis in dogs. Vet J 2011; 190: 408-411.
34. Maia C, Nunes M, Marques M et al. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exper Parasitol 2013; 135: 36-41.